484 related articles for article (PubMed ID: 7543841)
1. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.
Davis R; Whittington R
Drugs; 1995 Jun; 49(6):954-83. PubMed ID: 7543841
[TBL] [Abstract][Full Text] [Related]
2. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.
Peters DC; Noble S
Drugs; 1999 Feb; 57(2):233-60. PubMed ID: 10188764
[TBL] [Abstract][Full Text] [Related]
3. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.
Menkis AH; Martin J; Cheng DC; Fitzgerald DC; Freedman JJ; Gao C; Koster A; Mackenzie GS; Murphy GJ; Spiess B; Ad N
Innovations (Phila); 2012; 7(4):229-41. PubMed ID: 23123988
[TBL] [Abstract][Full Text] [Related]
4. Review and application of serine protease inhibition in coronary artery bypass graft surgery.
Engles L
Am J Health Syst Pharm; 2005 Sep; 62(18 Suppl 4):S9-14. PubMed ID: 16227196
[TBL] [Abstract][Full Text] [Related]
5. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
6. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass.
Waldow T; Krutzsch D; Wils M; Plötze K; Matschke K
Clin Hemorheol Microcirc; 2009; 42(4):269-77. PubMed ID: 19628892
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting.
Levy JH; Pifarre R; Schaff HV; Horrow JC; Albus R; Spiess B; Rosengart TK; Murray J; Clark RE; Smith P
Circulation; 1995 Oct; 92(8):2236-44. PubMed ID: 7554207
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery].
Corbeau JJ; Monrigal JP; Jacob JP; Cottineau C; Moreau X; Bukowski JG; Subayi JB; Delhumeau A
Ann Fr Anesth Reanim; 1995; 14(2):154-61. PubMed ID: 7486272
[TBL] [Abstract][Full Text] [Related]
9. Aprotinin in cardiac surgery.
Sodha NR; Boodhwani M; Bianchi C; Ramlawi B; Sellke FW
Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):151-60. PubMed ID: 16509811
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery.
Jamieson WR; Dryden PJ; O'Connor JP; Sadeghi H; Ansley DM; Merrick PM
Circulation; 1997 Nov; 96(9 Suppl):II-96-100; discussion II-100-1. PubMed ID: 9386082
[TBL] [Abstract][Full Text] [Related]
11. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
[TBL] [Abstract][Full Text] [Related]
12. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients.
Hardy JF; Desroches J; Belisle S; Perrault J; Carrier M; Robitaille D
Can J Anaesth; 1993 Jul; 40(7):625-31. PubMed ID: 7691426
[TBL] [Abstract][Full Text] [Related]
13. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
Bulutcu FS; Ozbek U; Polat B; Yalçin Y; Karaci AR; Bayindir O
Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162
[TBL] [Abstract][Full Text] [Related]
14. Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery.
Kunt AS; Darcin OT; Aydin S; Demir D; Selli C; Andac MH
J Thromb Thrombolysis; 2005 Jun; 19(3):197-200. PubMed ID: 16082607
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of aprotinin in cardiac surgery.
Levy JH
Orthopedics; 2004 Jun; 27(6 Suppl):s659-62. PubMed ID: 15239553
[TBL] [Abstract][Full Text] [Related]
16. Low-dose and high-dose aprotinin improve hemostasis in coronary operations.
Speekenbrink RG; Wildevuur CR; Sturk A; Eijsman L
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):523-30. PubMed ID: 8751522
[TBL] [Abstract][Full Text] [Related]
17. Effects of minimal-dose aprotinin on coronary artery bypass grafting.
Hayashida N; Isomura T; Sato T; Maruyama H; Kosuga K; Aoyagi S
J Thorac Cardiovasc Surg; 1997 Aug; 114(2):261-9. PubMed ID: 9270645
[TBL] [Abstract][Full Text] [Related]
18. The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting.
Bittner HB; Lemke J; Lange M; Rastan A; Mohr FW
Ann Thorac Surg; 2008 May; 85(5):1662-8. PubMed ID: 18442562
[TBL] [Abstract][Full Text] [Related]
19. Aprotinin vs. tranexamic acid in isolated coronary artery bypass surgery: A multicentre observational study.
Deloge E; Amour J; Provenchère S; Rozec B; Scherrer B; Ouattara A
Eur J Anaesthesiol; 2017 May; 34(5):280-287. PubMed ID: 28221207
[TBL] [Abstract][Full Text] [Related]
20. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
Santamaría A; Mateo J; Oliver A; Litvan H; Murillo J; Souto JC; Fontcuberta J
Haematologica; 2000 Dec; 85(12):1277-84. PubMed ID: 11114135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
